Lesson plan
Cemiplimab
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. It was approved for medical use in the United States in September 2018, in the European Union in June 2019. and in Australia in July 2020. Cemiplimab is the first approval by the US Food and Drug Administration of a medication specifically for advanced cutaneous squamous cell carcinoma. Cemiplimab is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Article summary
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. It was approved for medical use in the United States in September 2018, in the European Union in June 2019. and in Australia in July 2020. Cemiplimab is the first approval by the US Food and Drug Administration of a medication specifically for advanced cutaneous squamous cell carcinoma. Cemiplimab is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.